Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of biomarker in predicting sensitivity of bevacizumab

A bevacizumab and marker technology, applied in the field of biomedicine, can solve problems such as the difficulty of predicting the sensitivity of bevacizumab

Inactive Publication Date: 2021-12-24
QINGDAO MEDINTELL BIOMEDICAL CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the exact effect of bevacizumab on rectal tumors has not been fully elucidated, and the sensitivity of patients to bevacizumab is also difficult to predict

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of biomarker in predicting sensitivity of bevacizumab
  • Application of biomarker in predicting sensitivity of bevacizumab
  • Application of biomarker in predicting sensitivity of bevacizumab

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0066] Example 1, screening prediction marker

[0067] 1, data download and experimental object

[0068] Download gene expression data from GSE60331 from the GEO database, the specific link is https: / / www.ebi.ac.uk / ArrayExpress / experiments / e-geod-60331 / ? Query = GSE60331 +.

[0069] In the study of the above database, 59 patients retained tumor tissue before receiving Bevacu, and receiving Total Mesorectal Excision, TME surgery, according to the patient's treatment, according to DWORAK / The five levels divided the patient into two groups: Complete Remission (CR), also known as the response to R, the treatment failure group (Non-responder, NR) is also known as unreceptive in the database Marked as NR.

[0070] In the end, 21 samples were collected, and no reactors were 26 samples; in addition, the three samples of NJ 04 / 003T1, RVS 09 / 002M, NJ 04 / 003W3 were repeated to exclude batch effects. Eventually NR: R = 27: 23.

[0071] 2, data analysis

[0072] After obtaining the s...

Embodiment 2

[0075] Example 2, verification marker, marker combination prediction effect

[0076] The subject working curve (ROC), calculates AUC value, sensitivity, and specificity, and determines prediction efficiency of markers. KCNT2, FLJ33534, CACHD1, KCNT2 + FLJ33534, KCNT2 + CACHD1, FLJ33534 + CACHD1 ROC curve sequentially Figure 2-7 As shown, the AUC value is shown in Table 2.

[0077] Table 2. AUC value of marker or marker combination

[0078] Marker / combination AUC KCNT2 0.724637681 FLJ33534 0.782608696 Cachd1 0.787439614 Cachd1_kcnt2 0.790660225 Cachd1_flj33534 0.896940419 KCNT2_FLJ33534 0.843800322

[0079] The above results illustrate the markers provided by the present invention to predict the sensitivity of colorectal cancer in patients with pegs, and have high clinical application value.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention belongs to the field of biomedicine, and particularly relates to application of a biomarker in predicting sensitivity of bevacizumab. Specifically, biomarkers comprise KCNT2, FLJ33534, CACHD1, preferably, the prediction of the sensitivity of the bevacizumab is the prediction of the sensitivity of a rectal cancer patient to the bevacizumab.

Description

Technical field [0001] The invention belongs to the biomedical field, and more particularly to the use of biomarkers in predicting the sensitivity of bevili. Background technique [0002] Rectal Cancer refers to a malignant tumor that occurs at the junction of the rectum and the junction of the rectum, the junction of the rectum, the junction of the rectum. More than 80% of China's rectal cancer occurred in the anus, which can be found through rectal inspectors. The etiology of rectal cancer is still unclear. Most rectal cancer has evolved by adenoma, and experiencing hyperplasia, adenomas, cancer changes and corresponding chromosome changes, and cancer changes involve multi-gene participation. Although the cause is not clear, its related high risk factors are gradually known. [0003] The treatment of rectal cancer should take the principle of individualization, and the doctor will apply a variety of treatment means according to the patient's physical condition, the pathological...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6886G01N33/574
CPCC12Q1/6886G01N33/57419C12Q2600/158C12Q2600/106
Inventor 杨承刚王丹李雨晨
Owner QINGDAO MEDINTELL BIOMEDICAL CO LTD